Claims for Patent: 9,511,056

Summary for Patent: 9,511,056

Title:	Antiviral compounds
Abstract:	The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Bacon; Elizabeth M. (Burlingame, CA), Canales; Eda (San Mateo, CA), Cho; Aesop (Mountain View, CA), Cottell; Jeromy J. (Redwood City, CA), Desai; Manoj C. (Pleasant Hill, CA), Graupe; Michael (Pacifica, CA), Guo; Hongyan (San Mateo, CA), Halcomb; Randall L. (Foster City, CA), Kato; Darryl (San Francisco, CA), Kim; Choung U. (San Carlos, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Belmont, CA), Lazerwith; Scott E. (San Francisco, CA), Link; John O. (San Francisco, CA), Liu; Hongtao (Foster City, CA), Liu; Qi (Union City, CA), Mackman; Richard L. (Millbrae, CA), Mitchell; Michael L. (Hayward, CA), Parrish; Jay P. (Redwood City, CA), Pyun; Hyung-Jung (Fremont, CA), Saugier; Joseph H. (Livermore, CA), Schroeder; Scott D. (Foster City, CA), Sun; Jianyu (Surrey, CA), Taylor; James G. (San Mateo, CA), Trenkle; James D. (Oakland, CA), Tse; Winston C. (Redwood City, CA), Vivian; Randall W. (San Mateo, CA), Watkins; William J. (Saratoga, CA), Xu; Lianhong (Palo Alto, CA)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	14/280,478
Patent Claims:	1. A method of eliminating hepatitis C virus in a human patient in need thereof comprising administering to said human an effective amount of: (1) a compound of formula: ##STR01321## and (2) a NS5B polymerase inhibitor. 2. The method of claim 1, wherein the NS5B polymerase inhibitor is a nucleotide inhibitor of HCV NS5B polymerase. 3. The method of claim 2, wherein the human is treated without interferon. 4. The method of claim 3, wherein the human is treated without ribavirin. 5. The method of claim 3, wherein the human is treated with ribavirin. 6. The method of claim 3, wherein the human is infected with HCV genotype 1. 7. The method of claim 3, wherein the human is infected with HCV genotype 1a or 1b. 8. The method of claim 4, wherein the human is infected with HCV genotype 1. 9. The method of claim 4, wherein the human is infected with HCV genotype 1a or 1b.